Influence of NOS1 on Verbal Intelligence and Working Memory in Both Patients With Schizophrenia and Healthy Control Subjects

Neuropsychiatric Genetics Research Group, Department of Psychiatry, Trinity Health Sciences Bldg, St James's Hospital, Dublin 8, Ireland.
Archives of general psychiatry (Impact Factor: 13.75). 10/2009; 66(10):1045-54. DOI: 10.1001/archgenpsychiatry.2009.139
Source: PubMed

ABSTRACT Human and animal studies have implicated the gene NOS1 in both cognition and schizophrenia susceptibility.
To investigate whether a potential schizophrenia risk single-nucleotide polymorphism (rs6490121) identified in a recent genome-wide association study negatively influences cognition in patients with schizophrenia and healthy control subjects.
A comparison of both cases and controls grouped according to NOS1 genotype (GG vs AG vs AA) on selected measures of cognition in 2 independent samples. We tested for association between NOS1 rs6490121 and cognitive functions known to be impaired in schizophrenia (IQ, episodic memory, working memory, and attentional control) in an Irish sample. We then sought to replicate the significant results in a German sample.
Unrelated patients from general adult psychiatric inpatient and outpatient services and unrelated healthy volunteers from the general population were ascertained.
Patients with DSM-IV-diagnosed schizophrenia and healthy control subjects from independent samples of Irish (cases, n = 349; controls, n = 230) and German (cases, n = 232; controls, n = 1344) nationality.
A main effect of NOS1 genotype on verbal IQ and working memory was observed in the Irish sample where the homozygous carriers of the schizophrenia risk G allele performed poorly compared with the other genotype groups. These findings were replicated in the German sample, again with the GG genotype carriers performing below other genotype groups. Post hoc analysis of additional IQ measures (full-scale and performance IQ) in the German sample revealed that NOS1 GG carriers underperformed on these measures also.
NOS1 is associated with clinically significant variation in cognition. Whether this is a mechanism by which schizophrenia risk is increased (eg, via an influence on cognitive reserve) is yet to be confirmed.

  • Source
    • "Reif and colleagues (2011) also conducted an fNIRS study on rs41279104 and found that it played a significant role in prefrontal cortex during a verbal fluency task (working memory). For another SNP, rs6490121, Donohoe et al. (2009) found that it was significantly associated with working memory, but not attentional control in two independent samples. The same group of researchers also conducted an fMRI study (Rose et al, 2012) with a spatial working memory task on 48 healthy controls and found that the risk allele carriers exhibited altered activation at the prefrontal cortex. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Nitric oxide (NO), a gaseous neurotransmitter, has been implicated in the pathogenesis of schizophrenia. Accordingly, several polymorphisms of the gene that codes for the main NO-producing enzyme, the Nitric oxide synthase 1 (NOS1), have been found convey a risk for schizophrenia. This study examined the role of NOS1 gene polymorphisms in cognitive functions and related neural mechanism. First, with a sample of 580 schizophrenia patients and 720 healthy controls, we found that rs3782206 genotype had main effects on the 1-back task (P=0.005), the 2-back task (P=0.049), the AY condition of the dot-pattern expectancy [DPX] task (P=0.001), and the conflict effect of the attention network [ANT] test (P< 0.001 for RT differences and P=0.002 for RT ratio) and interaction effects with diagnosis on the BX condition of the DPX (P=0.009), the AY condition of the DPX (P< 0.001), and the Stroop conflict effect (P=0.003 for RT differences and P=0.038 for RT ratio). Simple effect analyses further showed that the schizophrenia risk allele (T) of rs3782206 was associated with poorer performance in 5 measures for the patients (1-back, P=0.025; BX, P=0.017; AY, P< 0.001; ANT conflict effect [RT differences], P=0.005; Stroop conflict effect [RT differences], P=0.019) and 3 measures for the controls ( for the 2-back task, P=0.042; for the ANT conlict effect [RT differences], P=0.013; for the ANT conflict effect [RT ratios], P=0.028). Then, with a separate sample of 78 healthy controls, we examined the association between rs3782206 and brain activation patterns during the N-back task and the Stroop task. Whole brain analyses found that the risk allele carriers showed reduced activation at the right inferior frontal gyrus (IFG) during both tasks. Finally, we examined functional connectivity seeded from the right IFG to the dorsolateral prefrontal cortex (DLPFC) and anterior cingulate cortex (ACC) under three conditions (the N-back task, the Stroop task, and the resting-state). Results showed reduced connectivity with the DLPFC for the risk allele carriers mainly in the Stroop task and the resting-state. Taken together, results of this study strongly suggested a link between NOS1 gene polymorphism at rs3782206 and cognitive functions and their neural underpinnings at the IFG. These results have important implications for our understanding of the neural mechanism underlying the association between NOS1 gene polymorphism and schizophrenia.Neuropsychopharmacology accepted article preview online, 10 December 2014. doi:10.1038/npp.2014.323.
    Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 12/2014; 40(6). DOI:10.1038/npp.2014.323 · 7.83 Impact Factor
  • Source
    • "In addition, Kawohl et al. (2008) demonstrated that rs41279104 risk allele carriers had decreased loudness dependence of auditory evoked potentials, which is a functional marker of serotonergic transmission, arguing for a connection between the NO and serotonin systems as also shown on the protein and the neuronal network (Kiss and Vizi, 2001) level. Also, the GWAS risk SNP rs6490121 was shown to be functional in respect to general intelligence, working memory and visual sensory processing as measured by the electroencephalogram event-related P1 response (Donohoe et al., 2009; O'Donoghue et al., 2012). Most of these effects could also be observed in healthy controls, and not only patients. "
    [Show abstract] [Hide abstract]
    ABSTRACT: NO is a pleiotropic signaling molecule and has an important role in cognition and emotion. In the brain, NO is produced by neuronal nitric oxide synthase (NOS-I, encoded by NOS1) coupled to the NMDA receptor via PDZ interactions; this protein-protein interaction is disrupted upon binding of NOS1 adapter protein (encoded by NOS1AP) to NOS-I. As both NOS1 and NOS1AP were associated with schizophrenia, we here investigated these genes in greater detail by genotyping new samples and conducting a meta-analysis of our own and published data. In doing so, we confirmed association of both genes with schizophrenia and found evidence for their interaction in increasing risk towards disease. Our strongest finding was the NOS1 promoter SNP rs41279104, yielding an odds ratio of 1.29 in the meta-analysis. As findings from heterologous cell systems have suggested that the risk allele decreases gene expression, we studied the effect of the variant on NOS1 expression in human post-mortem brain samples and found that the risk allele significantly decreases expression of NOS1 in the prefrontal cortex. Bioinformatic analyses suggest that this might be due the replacement of six transcription factor binding sites by two new binding sites as a consequence of proxy SNPs. Taken together, our data argue that genetic variance in NOS1 resulting in lower prefrontal brain expression of this gene contributes to schizophrenia liability, and that NOS1 interacts with NOS1AP in doing so. The NOS1-NOS1AP PDZ interface may thus well constitute a novel target for small molecules in at least some forms of schizophrenia.
    European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology 09/2013; DOI:10.1016/j.euroneuro.2013.09.005 · 5.40 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The development of a high performance parallel system or application is an evolutionary process -- both the code and the environment go through many changes during a program's lifetime -- and at each change, a key question for developers is: how and how much did the performance change? No existing performance tool provides the necessary functionality to answer this question. We report on the design and preliminary implementation of a tool that views each execution as a scientific experiment and provides the functionality to answer questions about a program's performance that span more than a single execution or environment.
    Supercomputing, ACM/IEEE 1997 Conference; 12/1997
Show more